Effect of ractopamine-hydrochloride and trenbolone acetate on longissimus muscle fiber area, diameter, and satellite cell numbers in cull beef cows.
The objective of this study was to evaluate the effects of coadministration of ractopamine-HCl (RAC) and trenbolone acetate plus estradiol (TBA) on LM fiber cross-sectional area (CSA), diameter, fiber-associated myonuclei, and satellite cell number. Culled crossbred beef cows (n = 98; 11 +/- 1.8 yr old; BCS 4.3 +/- 0.03) from a single ranch in south Florida were fed a concentrate diet for 92 d in a 2 x 2, randomized block design. Cows were blocked by BW on arrival into light (initial BW = 369.75 +/- 2.68 kg and end BW = 501.96 +/- 6.90 kg) and heavy (initial BW = 418.31 +/- 2.75 kg and end BW = 522.15 +/- 7.09 kg) groups before assignment to treatment. Factors included dietary treatment (0 or 15 ppm) and implant status (0 or 80 mg of trenbolone acetate + 16 mg of estradiol). Ractopamine was provided in the diet to 2 pens or half the treatments during the final 35 d of feeding. Cows were slaughtered on d 92. Forty-eight hours postmortem, the 6th-rib portions of the LM were obtained from 10 randomly selected carcasses from each treatment group (n = 40). Cryosections (12 mum) were immunostained for dystrophin and myosin heavy chain I or II for the measurement of fiber CSA and type, respectively. Fiber-associated nuclei and satellite cell numbers were measured in serial cryosections. There was a RAC x TBA interaction (P < 0.05). Type I fiber CSA and diameter were increased (P < 0.05) by TBA and RAC. Type I CSA and diameter were larger (P < 0.05) in TBA + RAC than RAC only. Type II fiber CSA and diameter were not affected by TBA (P = 0.48), RAC (P = 0.15), or TBA + RAC (P = 0.60). Satellite cell numbers and fiber-associated nuclei were not affected (P > 0.05) by implant status or ractopamine supplementation. These results indicate that TBA and RAC preferentially increase the size of type I fibers in cull cows.
Gonzalez
J M
JM
Department of Animal Sciences, University of Florida, Gainesville 32611, USA.
Carter
J N
JN
Johnson
D D
DD
Ouellette
S E
SE
Johnson
S E
SE
D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D045930:Anabolic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D002417:Cattle / Q000502:physiology*; D002452:Cell Count; D004032:Diet / Q000662:veterinary; D005260:Female; D016018:Least-Squares Analysis; D018485:Muscle Fibers, Skeletal / Q000166:cytology / Q000187:drug effects*; D018482:Muscle, Skeletal / Q000187:drug effects / Q000254:growth & development; D051763:PAX7 Transcription Factor / Q000032:analysis; D010627:Phenethylamines / Q000008:administration & dosage / Q000494:pharmacology*; D011897:Random Allocation; D032496:Satellite Cells, Skeletal Muscle / Q000166:cytology / Q000187:drug effects; D013997:Time Factors; D014204:Trenbolone Acetate / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology
D000318:Adrenergic beta-Agonists; D045930:Anabolic Agents; D051763:PAX7 Transcription Factor; D010627:Phenethylamines; C060897:ractopamine; D014204:Trenbolone Acetate